Elemento Lab

Publications

Found 194 results
Filters: First Letter Of Last Name is K  [Clear All Filters]
2020
Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Chen Y, Gardner K et al..  2020.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.. Cancers (Basel). 12(5)
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Han T, Goswami S, Hu Y, Tang F, Zafra MPaz, Murphy C, Cao Z, Poirier JT, Khurana E, Elemento O et al..  2020.  Lineage reversion drives WNT independence in intestinal cancer.. Cancer Discov.
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2020.  Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression.. medRxiv.
Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al..  2020.  Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression.. medRxiv.
Matrai C, Motanagh S, Mirabelli S, Ma L, He B, Chapman-Davis E, Kurtis B, Elemento O, Mosquera JMiguel, Ellenson LH.  2020.  Molecular Profiles of Mixed Endometrial Carcinoma.. Am J Surg Pathol. 44(8):1104-1111.
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.
Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J et al..  2020.  Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. Cancer Cell. 37(5):655-673.e11.
Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J et al..  2020.  Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. Cancer Cell. 37(5):655-673.e11.
Alsaleem MA, Ball G, Toss MS, Raafat S, Aleskandarany M, Joseph C, Ogden A, Bhattarai S, Rida PCG, Khani F et al..  2020.  A novel prognostic two-gene signature for triple negative breast cancer.. Mod Pathol.
Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Publisher Correction: Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1309.
Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Publisher Correction: Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1309.
Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Publisher Correction: Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1309.
Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Publisher Correction: Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1309.
Segal E, Zhang F, Lin X, King G, Shalem O, Shilo S, Allen WE, Alquaddoomi F, Altae-Tran H, Anders S et al..  2020.  Publisher Correction: Building an international consortium for tracking coronavirus health status.. Nat Med. 26(8):1309.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.
Conteduca V, Ku S-Y, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JMiguel et al..  2020.  SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.. Mol Cancer Ther. 19(5):1157-1164.
Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR et al..  2020.  TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.. Cell. 182(2):297-316.e27.
Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR et al..  2020.  TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.. Cell. 182(2):297-316.e27.
2019
Madhukar NS, Khade PK, Huang L, Gayvert K, Galletti G, Stogniew M, Allen JE, Giannakakou P, Elemento O.  2019.  A Bayesian machine learning approach for drug target identification using diverse data types.. Nat Commun. 10(1):5221.